FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.4  |  FHIR Version n/a  User: [n/a]

1495581000168106: List of Medicines for Brand Consideration reference set (foundation metadata concept)


Status: current, Primitive. Date: 30-Sep 2020. Module: Third party reference set module

Descriptions:

Id Description Lang Type Status Case? Module
4462321000168116 List of Medicines for Brand Consideration reference set (foundation metadata concept) en Fully specified name Active Initial character case insensitive Third party reference set module
4462331000168118 List of Medicines for Brand Consideration reference set en Synonym Active Initial character case insensitive Third party reference set module
4462411000168119 List of Medicines for Brand Consideration (LMBC) reference set en Synonym Active Initial character case insensitive Third party reference set module
4462641000168118 <p>Supports the identification of AMT Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP) concepts associated with the List of Medicines for Brand Consideration (LMBC) that forms part of the Active Ingredient Prescribing initiative. Under the <i>National Health (Pharmaceutical Benefits) Regulations 2017</i>, the <i>Repatriation Pharmaceutical Benefits Scheme Instrument 2013</i> and <i>MRCA Pharmaceutical Benefits Scheme Instrument 2013</i>, all PBS and RPBS prescriptions must be prepared by active ingredient, the brand may additionally be identified if a prescriber considers it necessary. The LMBC supports prescribers' decision-making regarding the inclusion of brand on a prescription.</p><p>This reference set can be used by prescribing software vendors to identify medications for brand consideration to meet Active Ingredient Prescribing requirements.</p><p><b>Target Client:&nbsp;</b>This reference set was developed by the National Clinical Terminology Service for the Australian Government Department of Health and Aged Care to support the Active Ingredient Prescribing initiative, and can be used by developers to assist with the requirements.</p> en Definition Active Case sensitive Third party reference set module


1324 members. Search Members:

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
List of Medicines for Brand Consideration reference set Is a Reference sets for Medications true Inferred relationship Some
List of Medicines for Brand Consideration reference set Is a Simple type reference set true Inferred relationship Some
List of Medicines for Brand Consideration reference set Developed by Australian Government Department of Health and Aged Care true Inferred relationship Some 1570063879

Members
ethinylestradiol 30 microgram + levonorgestrel 150 microgram tablet [21 tablets] (&) inert substance tablet [7 tablets], 2 x 28 tablets (medicinal product pack)
levonorgestrel 150 microgram + ethinylestradiol 30 microgram tablet [21] (&) inert substance tablet [7], 28
levonorgestrel 150 microgram + ethinylestradiol 30 microgram tablet [21] (&) inert substance tablet [7], 3 x 28
levonorgestrel 150 microgram + ethinylestradiol 30 microgram tablet [21] (&) inert substance tablet [7], 4 x 28
levonorgestrel 150 microgram + ethinylestradiol 30 microgram tablet, 21
levonorgestrel 150 microgram + ethinylestradiol 30 microgram tablet, 4 x 21
levonorgestrel 50 microgram + ethinylestradiol 30 microgram tablet
norethisterone 1 mg + ethinylestradiol 35 microgram tablet
norethisterone 1 mg + ethinylestradiol 35 microgram tablet [21] (&) inert substance tablet [7], 28
norethisterone 1 mg + ethinylestradiol 35 microgram tablet [21] (&) inert substance tablet [7], 3 x 28
norethisterone 1 mg + ethinylestradiol 35 microgram tablet [21] (&) inert substance tablet [7], 4 x 28
norethisterone 1 mg + ethinylestradiol 35 microgram tablet, 21
norethisterone 1 mg + ethinylestradiol 35 microgram tablet, 4 x 21
norethisterone 500 microgram + ethinylestradiol 35 microgram tablet
norethisterone 500 microgram + ethinylestradiol 35 microgram tablet [21] (&) inert substance tablet [7], 28
norethisterone 500 microgram + ethinylestradiol 35 microgram tablet [21] (&) inert substance tablet [7], 4 x 28
norethisterone 500 microgram + ethinylestradiol 35 microgram tablet, 21
norethisterone 500 microgram + ethinylestradiol 35 microgram tablet, 4 x 21
levonorgestrel 75 microgram + ethinylestradiol 40 microgram tablet
levonorgestrel 125 microgram + ethinylestradiol 50 microgram tablet
levonorgestrel 125 microgram + ethinylestradiol 50 microgram tablet [21] (&) inert substance tablet [7], 2 x 28
levonorgestrel 125 microgram + ethinylestradiol 50 microgram tablet [21] (&) inert substance tablet [7], 28
levonorgestrel 125 microgram + ethinylestradiol 50 microgram tablet [21] (&) inert substance tablet [7], 3 x 28
levonorgestrel 125 microgram + ethinylestradiol 50 microgram tablet [21] (&) inert substance tablet [7], 4 x 28
everolimus 1 mg tablet
everolimus 1 mg tablet, 100
everolimus 1 mg tablet, 120
everolimus 1 mg tablet, 50
everolimus 1 mg tablet, 60
everolimus 10 mg tablet
everolimus 10 mg tablet, 10
everolimus 10 mg tablet, 100
everolimus 10 mg tablet, 120
everolimus 10 mg tablet, 30
everolimus 10 mg tablet, 50 tablets (medicinal product pack)
everolimus 10 mg tablet, 60
everolimus 10 mg tablet, 90
everolimus 2 mg dispersible tablet
everolimus 2 mg dispersible tablet, 100
everolimus 2 mg dispersible tablet, 120
everolimus 2 mg dispersible tablet, 30
everolimus 2 mg dispersible tablet, 50
everolimus 2 mg dispersible tablet, 60
everolimus 2.5 mg tablet
everolimus 2.5 mg tablet, 10
everolimus 2.5 mg tablet, 30
everolimus 2.5 mg tablet, 50
everolimus 2.5 mg tablet, 60
everolimus 2.5 mg tablet, 90
everolimus 250 microgram tablet
everolimus 250 microgram tablet, 120
everolimus 250 microgram tablet, 60
everolimus 3 mg dispersible tablet
everolimus 3 mg dispersible tablet, 100
everolimus 3 mg dispersible tablet, 120
everolimus 3 mg dispersible tablet, 30
everolimus 3 mg dispersible tablet, 50
everolimus 3 mg dispersible tablet, 60
everolimus 5 mg dispersible tablet
everolimus 5 mg dispersible tablet, 100
everolimus 5 mg dispersible tablet, 120
everolimus 5 mg dispersible tablet, 30
everolimus 5 mg dispersible tablet, 50
everolimus 5 mg dispersible tablet, 60
everolimus 5 mg tablet
everolimus 5 mg tablet, 10
everolimus 5 mg tablet, 100
everolimus 5 mg tablet, 120
everolimus 5 mg tablet, 30
everolimus 5 mg tablet, 50 tablets (medicinal product pack)
everolimus 5 mg tablet, 60
everolimus 5 mg tablet, 90
everolimus 500 microgram tablet
everolimus 500 microgram tablet, 120
everolimus 500 microgram tablet, 60
everolimus 750 microgram tablet
everolimus 750 microgram tablet, 120
everolimus 750 microgram tablet, 60
fentanyl 100 microgram/actuation nasal spray, 1 actuation
fentanyl 100 microgram/actuation nasal spray, 10 actuations
fentanyl 100 microgram/actuation nasal spray, 10 x 1 actuation
fentanyl 100 microgram/actuation nasal spray, 2 x 1 actuation
fentanyl 100 microgram/actuation nasal spray, 20 actuations
fentanyl 100 microgram / 1 actuation nasal spray, 4 x 8 actuations (medicinal product pack)
fentanyl 100 microgram/actuation nasal spray, 40 actuations
fentanyl 100 microgram/actuation nasal spray, 6 x 1 actuation
fentanyl 100 microgram/actuation nasal spray, 8 actuations
fentanyl 100 microgram/actuation nasal spray, 8 x 1 actuation
fentanyl 100 microgram/actuation nasal spray, actuation
fentanyl 100 microgram/hour patch
fentanyl 100 microgram/hour patch, 1
fentanyl 100 microgram/hour patch, 10
fentanyl 100 microgram/hour patch, 2
fentanyl 100 microgram/hour patch, 3
fentanyl 100 microgram/hour patch, 4
fentanyl 100 microgram/hour patch, 5
fentanyl 100 microgram/hour patch, 7
fentanyl 100 microgram/hour patch, 8
fentanyl 100 microgram orally disintegrating tablet
fentanyl 100 microgram orally disintegrating tablet, 28
fentanyl 100 microgram orally disintegrating tablet, 4

Start Previous Page 5 of 14 Next End


Reference Sets

Australian dialect reference set

Reference set descriptor

Back to Start